| Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer C Xavier, I Vaneycken, M D’huyvetter, J Heemskerk, M Keyaerts, C Vincke, ... Journal of Nuclear Medicine 54 (5), 776-784, 2013 | 242 | 2013 |
| Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody M D'Huyvetter, C Vincke, C Xavier, A Aerts, N Impens, S Baatout, ... Theranostics 4 (7), 708, 2014 | 218 | 2014 |
| Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle Y Dekempeneer, M Keyaerts, A Krasniqi, J Puttemans, S Muyldermans, ... Expert opinion on biological therapy 16 (8), 1035-1047, 2016 | 163 | 2016 |
| Immuno-imaging using nanobodies I Vaneycken, M D’huyvetter, S Hernot, J De Vos, C Xavier, N Devoogdt, ... Current Opinion in Biotechnology 22 (6), 877-881, 2011 | 162 | 2011 |
| 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment M D'Huyvetter, J De Vos, C Xavier, M Pruszynski, YGJ Sterckx, S Massa, ... Clinical cancer research 23 (21), 6616-6628, 2017 | 158 | 2017 |
| Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours P Debie, C Lafont, M Defrise, I Hansen, DM van Willigen, ... Journal of Controlled Release 317, 34-42, 2020 | 154 | 2020 |
| PET imaging of macrophage mannose receptor–expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments A Blykers, S Schoonooghe, C Xavier, K D’hoe, D Laoui, M D’Huyvetter, ... Journal of Nuclear Medicine 56 (8), 1265-1271, 2015 | 154 | 2015 |
| Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer M D’Huyvetter, C Xavier, V Caveliers, T Lahoutte, S Muyldermans, ... Expert opinion on drug delivery 11 (12), 1939-1954, 2014 | 143 | 2014 |
| Same-day imaging using small proteins: clinical experience and translational prospects in oncology A Krasniqi, M D’Huyvetter, N Devoogdt, FY Frejd, J Sörensen, A Orlova, ... Journal of Nuclear Medicine 59 (6), 885-891, 2018 | 128 | 2018 |
| 18F-nanobody for PET imaging of HER2 overexpressing tumors C Xavier, A Blykers, I Vaneycken, M D'Huyvetter, J Heemskerk, T Lahoutte, ... Nuclear medicine and biology 43 (4), 247-252, 2016 | 117 | 2016 |
| Theranostics in immuno-oncology using nanobody derivatives Q Lecocq, Y De Vlaeminck, H Hanssens, M D'Huyvetter, G Raes, ... Theranostics 9 (25), 7772, 2019 | 110 | 2019 |
| SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis S Put, S Schoonooghe, N Devoogdt, E Schurgers, A Avau, T Mitera, ... Journal of Nuclear Medicine 54 (5), 807-814, 2013 | 101 | 2013 |
| Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer M Pruszynski, M D’Huyvetter, F Bruchertseifer, A Morgenstern, T Lahoutte Molecular Pharmaceutics 15 (4), 1457-1466, 2018 | 100 | 2018 |
| Development of 177Lu‐nanobodies for radioimmunotherapy of HER2‐positive breast cancer: evaluation of different bifunctional chelators M D'Huyvetter, A Aerts, C Xavier, I Vaneycken, N Devoogdt, M Gijs, ... Contrast Media & Molecular Imaging 7 (2), 254-264, 2012 | 97 | 2012 |
| Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies M Lemaire, M D'Huyvetter, T Lahoutte, E Van Valckenborgh, E Menu, ... Leukemia 28 (2), 444-447, 2014 | 89 | 2014 |
| Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients M D’Huyvetter, J De Vos, V Caveliers, I Vaneycken, J Heemskerk, ... Journal of Nuclear Medicine 62 (8), 1097-1105, 2021 | 84 | 2021 |
| Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer M Evazalipour, M D'Huyvetter, BS Tehrani, M Abolhassani, K Omidfar, ... Contrast Media & Molecular Imaging 9 (3), 211-220, 2014 | 76 | 2014 |
| Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma A Krasniqi, M D'Huyvetter, C Xavier, K Van der Jeught, S Muyldermans, ... Molecular cancer therapeutics 16 (12), 2828-2839, 2017 | 75 | 2017 |
| Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies J Puttemans, Y Dekempeneer, JL Eersels, H Hanssens, P Debie, ... Cancers 12 (4), 1017, 2020 | 56 | 2020 |
| Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior Y Dekempeneer, T Bäck, E Aneheim, H Jensen, J Puttemans, C Xavier, ... Molecular Pharmaceutics 16 (8), 3524-3533, 2019 | 54 | 2019 |
